Advancing Therapeutic Development for Pain and Opioid Use Disorders through Public-Private Partnerships: A Workshop
October 11th, 2017
to October 12th, 2017
About the Event
At the request of Dr. Francis Collins, NIH hosted three small meetings in June and July 2017 focused on creating public-private partnerships to address the urgent public health need associated with opioids. NIH is joining with private partners in the pharmaceutical industry and the research community to launch an opioid research initiative to cut in half the amount of time required to develop new therapies for 1) safe, more effective strategies for pain management; 2) new and innovative opioid addiction treatments; and 3) overdose reversal interventions. The Forum on Neuroscience and Nervous System Disorders will host a public workshop bringing together key stakeholders to advance the discussions that emerged from the three NIH meetings to address the opioid epidemic, and examine potential implementation barriers and opportunities related to the proposed approaches discussed.
Review the state of the science for opioid and non-addictive pain treatments.
Provide an overview of emerging pain models, including those in the peripheral nervous system (e.g., induced pluripotent stem cells and human experimental biology).
Discuss the progress on the identification and validation of targets and biomarkers
Explore whether there is a systematic methodology to validating biomarkers to determine their usefulness.
Examine approaches to testing new formulations and drugs, and discuss the patient populations needed for those clinical trials.
Consider the formulation of promising pain medications—beyond opioid analgesics—that may have been shelved by companies.
Consider regulatory issues related to the approval of pain medications and discuss potential opportunities to address those challenges.
Explore opportunities and challenges to changing the formulation of marketed prescription opioids to decrease misuse, addiction, and potential overdoses (e.g., different delivery systems and anti-tampering mechanisms).
Discuss public-private partnerships that might facilitate and de-risk the development of drugs to treat overdoses and non-opioid therapeutics for pain (e.g., an Accelerating Medicines Partnership [AMP] for pain). Highlight lessons learned from industry and opportunities to advance the development of these drugs (e.g., a designated clinical trial network for pain).